That's a risk adjusted current valuation. So, the derisked, success case upside is much greater.
I had a look at the initial MST August 22 research report which gives more detail on the risk success factors used - 12% and 20% for the different tests/products. And with the 12% factor on the much bigger ovarian cancer potential revenues. Success multiplies the upside here a long way above the current valuation they give.
Then there is further upside from any pipeline success broadening the product range of Exosome based tests.
All about Risk/Reward. Risk seems to be reducing with their success. Reward is massive. The timeline for derisking and initial commercial success looks to be nearing a few inflexion points.
- Forums
- ASX - By Stock
- Inoviq new Research Report
That's a risk adjusted current valuation. So, the derisked,...
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
53.0¢ |
Change
0.005(0.95%) |
Mkt cap ! $48.77M |
Open | High | Low | Value | Volume |
53.0¢ | 53.0¢ | 53.0¢ | $644 | 1.215K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5885 | 53.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
54.5¢ | 1124 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5885 | 0.530 |
1 | 5785 | 0.525 |
3 | 8384 | 0.520 |
4 | 17252 | 0.515 |
2 | 5775 | 0.510 |
Price($) | Vol. | No. |
---|---|---|
0.545 | 1124 | 2 |
0.550 | 6500 | 1 |
0.560 | 6130 | 2 |
0.580 | 18091 | 1 |
0.585 | 10000 | 1 |
Last trade - 13.16pm 29/04/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |